These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 15865226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [Abstract] [Full Text] [Related]

  • 4. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH.
    Antivir Ther; 2009 Mar; 14(2):203-10. PubMed ID: 19430095
    [Abstract] [Full Text] [Related]

  • 5. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS.
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [Abstract] [Full Text] [Related]

  • 6. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z.
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [Abstract] [Full Text] [Related]

  • 7. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL.
    Antivir Ther; 2009 Apr; 14(5):679-85. PubMed ID: 19704171
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G, Cui Z, Wang B, Yao J, Zeng M.
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [Abstract] [Full Text] [Related]

  • 10. [Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B].
    Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M.
    Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):284-92. PubMed ID: 14695695
    [Abstract] [Full Text] [Related]

  • 11. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN, Liaw YF.
    Antivir Ther; 2006 Dec; 11(7):947-52. PubMed ID: 17302259
    [Abstract] [Full Text] [Related]

  • 12. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS.
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA.
    N Engl J Med; 1999 Oct 21; 341(17):1256-63. PubMed ID: 10528035
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF.
    Hepatology; 1999 Mar 21; 29(3):889-96. PubMed ID: 10051494
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
    Kim JH, Yu SK, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Lee CH, Byun KS.
    J Gastroenterol Hepatol; 2007 Aug 21; 22(8):1220-5. PubMed ID: 17532786
    [Abstract] [Full Text] [Related]

  • 16. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ.
    J Gastroenterol Hepatol; 2005 Jun 21; 20(6):844-9. PubMed ID: 15946130
    [Abstract] [Full Text] [Related]

  • 17. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H, Ma LX, Xu WS, Zhang HY, Yu LJ, Duan HY.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar 21; 11(3):173-5. PubMed ID: 12681068
    [Abstract] [Full Text] [Related]

  • 18. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.
    Hepatobiliary Pancreat Dis Int; 2004 May 21; 3(2):188-93. PubMed ID: 15138107
    [Abstract] [Full Text] [Related]

  • 19. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL, Schiff ER, Mitchell M, Casey DE, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N.
    Hepatology; 1999 Oct 21; 30(4):1082-7. PubMed ID: 10498663
    [Abstract] [Full Text] [Related]

  • 20. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct 21; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.